Discipline of Pharmacology, Adelaide Medical School, The University of Adelaide, Adelaide, SA, 5005, Australia.
Department of Clinical Pharmacology, The Queen Elizabeth Hospital, Woodville, SA, 5011, Australia.
Br J Clin Pharmacol. 2018 Oct;84(10):2433-2442. doi: 10.1111/bcp.13704. Epub 2018 Aug 7.
Although therapeutic drug monitoring of plasma mycophenolic acid (MPA) concentrations has been recommended to individualize dosage in transplant recipients, little is known regarding lymphocyte concentrations of MPA, where MPA inhibits inosine monophosphate dehydrogenase (IMPDH). This study investigated the utility of measuring predose MPA concentrations in peripheral blood mononuclear cells (C ) and predose IMPDH activity, as predictors of graft rejection in renal transplant recipients.
Forty-eight patients commencing mycophenolate mofetil (1 g twice daily) in combination with tacrolimus and prednisolone were recruited. Blood was collected for determination of trough total (C ) and unbound (C ) plasma MPA concentrations. Peripheral blood mononuclear cells were isolated for determination of C and IMPDH activity. The incidence of rejection within 2 days of sample collection was determined histologically and classified according to the Banff 2007 criteria.
There was no association between MPA C and C (r = 0.28, P = 0.06), however, MPA C were weakly correlated with MPA C (r = 0.42, P = 0.013). Multivariate analysis indicated that MPA C was the only covariate independently associated with rejection (FDR-adjusted P = 0.033). The receiver operating characteristic area under the curve (AUC) for the prediction of severe rejection using MPA C was 0.75 (P = 0.013), with 73% sensitivity and specificity at a C threshold of 0.5 ng 10 cells. However, predose IMPDH activity was not a predictor of rejection (P > 0.15).
MPA C measurement within the early post-transplant period may be useful to facilitate early titration of MPA dosing to significantly reduce rejection.
虽然已经推荐了对血浆麦考酚酸(MPA)浓度进行治疗药物监测,以实现对移植受者的剂量个体化,但对 MPA 的淋巴细胞浓度知之甚少,而 MPA 抑制肌苷单磷酸脱氢酶(IMPDH)。本研究调查了测量外周血单个核细胞(C)中 MPA 浓度和 MPA 浓度的预剂量 IMPDH 活性,作为肾移植受者移植物排斥的预测因子。
招募了 48 名开始接受吗替麦考酚酯(1g 每日两次)联合他克莫司和泼尼松龙治疗的患者。采集血液以确定谷总(C)和游离(C)血浆 MPA 浓度。分离外周血单个核细胞以确定 C 和 IMPDH 活性。通过组织学确定采集样本后 2 天内排斥的发生率,并根据 2007 年 Banff 标准进行分类。
MPA C 和 C 之间没有关联(r = 0.28,P = 0.06),但是 MPA C 与 MPA C 呈弱相关(r = 0.42,P = 0.013)。多变量分析表明,MPA C 是唯一与排斥相关的协变量(经 FDR 调整的 P = 0.033)。使用 MPA C 预测严重排斥的受试者工作特征曲线(ROC)下面积(AUC)为 0.75(P = 0.013),MPA C 阈值为 0.5ng/10 细胞时,敏感性和特异性分别为 73%。然而,预剂量 IMPDH 活性不是排斥的预测因子(P>0.15)。
在移植后早期测量 MPA C 可能有助于调整 MPA 剂量以显著降低排斥反应。